Data Insights

TILT-123 by TILT Biotherapeutics for Peritoneal Cancer: Likelihood of Approval

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - TILT-123 in Peritoneal Cancer

Data Insights

TILT-123 by TILT Biotherapeutics for Fallopian Tube Cancer: Likelihood of Approval

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TILT-123 in Fallopian Tube Cancer

Data Insights

TILT-123 by TILT Biotherapeutics for Head And Neck Cancer: Likelihood of Approval

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Head And Neck Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - TILT-123 in Head And Neck Cancer

Data Insights

TILT-123 by TILT Biotherapeutics for Ovarian Cancer: Likelihood of Approval

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - TILT-123 in Ovarian Cancer

Data Insights

TILT-123 by TILT Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - TILT-123 in Non-Small Cell Lung Cancer

Data Insights

TILT-123 by TILT Biotherapeutics for Solid Tumor: Likelihood of Approval

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - TILT-123 in Solid Tumor

Data Insights

TILT-123 by TILT Biotherapeutics for Melanoma: Likelihood of Approval

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - TILT-123 in Melanoma

Data Insights

TILT-123 by TILT Biotherapeutics for Sarcomas: Likelihood of Approval

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - TILT-123 in Sarcomas